The ATS Keynote Series continues Monday with addresses on patient safety and the latest research on cystic fibrosis—both presented by leaders in their fields.
Each day of ATS 2017, the series highlights state-of-the-art lectures about major discoveries in pulmonary, critical care, and sleep medicine. Two sessions are presented from 8:15 to 9 a.m. each day, when no other programming is scheduled.
Peter Pronovost, MD, PhD
Toward Eliminating All Harms (K3)
Salon A-C (South Building, Street Level)
Walter E. Washington Convention Center
Peter Pronovost, MD, PhD, will review his efforts to reduce infections and evaluate safety efforts. He is senior vice president for patient safety and quality at Johns Hopkins Medicine and the director of the Armstrong Institute for Patient Safety and Quality at Johns Hopkins.
Dr. Pronovost developed scientifically proven methods of reducing infections, including a checklist protocol associated with central line catheters in ICUs. He has written a book, “Safe Patients, Smart Hospitals: How One Doctor’s Checklist Can Help Us Change Health Care From the Inside Out,” and was named by Time magazine as one of the world’s 100 “most influential people” for his work.
Michael J. Welsh, MD
Cystic Fibrosis Lung Disease: Looking Back and Looking Forward (K4)
Salon G-I (South Building, Street Level)
Walter E. Washington Convention Center
Keynote speaker Michael J. Welsh, MD, has helped expand the understanding of the biology and pathogenesis of cystic fibrosis, and the development of new CF treatments. He also is investigating the biology of protons and acid-sensing ion channels involved in normal and pathological neuronal function.
Dr. Welsh is the Roy J. Carver Biomedical Research Chair in Internal Medicine and Molecular
Physiology and Biophysics, director of the University of Iowa Cystic Fibrosis Research Center, and director of the Pappajohn Biomedical Institute at the Roy J. and Lucille A. Carver College of Medicine of the University of Iowa.
Cystic Fibrosis Lung Disease: Looking Back and Looking Forward (K4) is supported by educational grants from Vertex Pharmaceuticals, Inc. and Gilead Sciences, Inc.